Guggenheim raised the firm’s price target on Oruka Therapeutics (ORKA) to $125 from $60 and keeps a Buy rating on the shares. Ahead of the Phase 2a EVERLAST-A study topline data readout in Q2, the firm says its base-case assumes ORKA-001 efficacy on par with AbbVie’s (ABBV) Skyrizi but adds that it thinks there is a real potential for ORKA-001 to produce efficacy that is superior to Skyrizi given the dose exposure relationship with Skyrizi.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORKA:
- Oruka Therapeutics files $1B mixed securities shelf
- ORKA-001 Phase 1 Completion: What Oruka’s First-in-Human Milestone Means for Investors
- Oruka Therapeutics price target raised to $86 from $58 at Leerink
- Oruka Therapeutics price target raised to $72 from $47 at Stifel
- Oruka Therapeutics price target raised to $50 from $48 at Barclays